PITTSBURGH, March 29 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Olanzapine Tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg strengths. Olanzapine Tablets are the generic version of Eli Lilly and Company's Zyprexa^® Tablets, which has annual U.S. sales of approximately $2.8 billion.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

SOURCE Mylan Laboratories Inc.
03/29/2005
CONTACT: Media: Heather Bresch, Investor: Kris King, both of Mylan Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com